2 / 7
Page 16
Volume 3
Journal of Neurology and Clinical Neuroscience
Neurology 2019 | Neuropsychology 2019 | Drug Delivery Summit 2019
June 24-25, 2019
June 24-25, 2019 | Rome, Italy
Neurology and Healthcare
3
rd
WorldDrug Delivery and Formulations Summit
Clinical and Experimental Neuropsychology
4
th
International Conference on
International Conference on
&
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
Muhammad Muzamil Khan
1,2
, Asadullah Madni
2
, Nina Filipczek, Jiayi Pan
1
, Nayab Tahir
2
, Hassan Shah
2
, Vladimir Torchilin
1
1
Northeastern University, USA
2
The Islamia University of Bahawalpur, Pakistan
L
ipid-Polymer Hybrid Nanoparticles (LPHNP) are novel delivery systems for controlled drug delivery at tumor sites.
The superior biocompatible properties of lipid and structural advantages of polymer can be obtained via this system
for controlled drug delivery. In the present study, cisplatin- loaded lipid-chitosan hybrid nanoparticles were formulated by
the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid.
Formulationswithvariouschitosantolipidratiowereinvestigatedtoobtaintheoptimalparticlesize,encapsulationefficiency
and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a
size range of 181-245 nm and a zeta potential range of 20-30 mV. Compatibility among the components and the stability of
formulation were demonstrated with FTIR analysis and thermal studies, respectively. The therapeutic efficacy and cellular
interaction of cisplatin-loaded LPHNPwere investigated using in vitro cell-based assays inA2780/ADR ovarian carcinoma
cell line. Additionally, the cisplatin loaded LPHNP exhibited a low toxicity profile in rats. The in-vivo pharmacokinetics
study also proved a controlled delivery of cisplatin with enhanced mean residual time and half-life. Our studies suggested
that the cisplatin- loaded LPHNP being a promising platform for controlled delivery of cisplatin in cancer therapy.
Biography
Muhammad Muzamil Khan is a PhD research Scholar at Northeastern University, Boston, USA. He is working now on Folate-targeted
Lipid-polymer Hybrid Nanoparticles for the targeted and controlled delivery of cisplatin for effective treatment of ovarian cancer. He is
interested in Co- delivery of siRNA and chemotherapeutic agents for the effective treatment of cancer.
muzamilpharmacist@gmail.comJ Neurol Clin Neurosci, Volume 3